9EKD image
Deposition Date 2024-12-02
Release Date 2025-02-12
Last Version Date 2025-08-27
Entry Detail
PDB ID:
9EKD
Title:
Structure of a C1r Zymogen Fragment Bound to SALO
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.28 Å
R-Value Free:
0.28
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 32 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Salivary anti-complement protein
Chain IDs:A, C (auth: B)
Chain Length:104
Number of Molecules:2
Biological Source:Lutzomyia longipalpis
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Complement C1r subcomponent
Gene (Uniprot):C1R
Mutagens:S654A
Chain IDs:B (auth: C), D
Chain Length:409
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
TYS A TYR modified residue
Ligand Molecules
Primary Citation
Blocking activation of the C1r zymogen defines a novel mode of complement inhibition.
J.Biol.Chem. 301 108301 108301 (2025)
PMID: 39947467 DOI: 10.1016/j.jbc.2025.108301

Abstact

Many hematophagous organisms secrete inhibitors of the coagulation and complement systems as constituents of their salivary fluid. Whereas previous studies on salivary gland extracts from the sandfly Lutzomyia longipalpis identified SALO (salivary anticomplement from L. longipalpis) as a potent inhibitor of the classical complement pathway (CP), its precise mechanism of action has remained elusive. Here, we show that SALO inhibits the CP by binding selectively to the C1r zymogen. Using surface plasmon resonance, we found that SALO expressed by human embryonic kidney 293(T) cells (eSALO-WT) bound with nanomolar affinity to the zymogen of complement protease C1r (pro-C1r), but that it did not bind the enzymatically active form of C1r. To gain insight into the structural basis for CP inhibition by SALO, we solved a 3.3 Å resolution crystal structure of eSALO-WT bound to a recombinant form of C1r that was engineered to remain in a zymogen-like state (zC1r-12SP). eSALO-WT formed extensive interactions with the zymogen activation loop of zC1r-12SP, including groups derived from residues R463 and I464, which compose its scissile peptide bond. Although the interactions with R463 and I464 were mediated by side-chain sulfation of eSALO-WT at position Y51, we found that this modification enhanced the potency of SALO but was not required for its activity. Consistent with our structural observations, subsequent studies showed that eSALO-WT binding to pro-C1r blocked its activation and thereby inhibited the CP in hemolytic assays of complement function. Together, our results define a new mode of inhibiting complement by blocking the farthest upstream enzymatic reaction of the CP.

Legend

Protein

Chemical

Disease

Primary Citation of related structures